Outcome of Indoor Covid Cases with Moderate to Severe Disease; Convalescent Plasma Transfusion vs Conventional Therapy
DOI:
https://doi.org/10.51985/JBUMDC202260Keywords:
SARS COV-2, Convalescent plasma transfusion, COVID PCR, Donor Eligibility CriteriaAbstract
Objectives: Global COVID-19 epidemic has been therapeutic challenge. Convalescent plasma is observed to improve
clinical outcomes. This research aims to study whether convalescent plasma therapy reduces the mortality and duration
of hospitalization in moderate to severe Covid.
Study Design and Setting: This interventional study was conducted after ethical approval at RIUT COVID-19 center
from1stJune-30th Nov 2020.
Methodology: Hundred Covid patients included; Total 100 hospitalized adult SARS Cov-2 PCR positive with moderate
to severe disease who agreed for convalescent plasma transfusion were included. Fifty in plasma transfusion group and
fifty in conventional therapy group. Those with contraindications for plasma transfusion, delayed presentation, indoor stay
<5 days were excluded. Convalescent plasma was obtained from donors with prior documented SARS CoV-2 infection
meeting donor eligibility criteria. 50 cases received convalescent plasma and50 received conventional therapy. Hospital
stay and outcome documented.
Results: Amongst 100 Covid cases; 44 females and 56 males; mean age 57.88+11.95 years, 74% had moderate covid and
26% severe. Fifty cases received conventional therapy for Covid and 50 received plasma transfusion. Both groups comparable
for gender, age, smoking, obesity, and disease severity. Invasive ventilation administered in 25% and was associated with
mortality (p=0.004). Mortality observed in 29 cases; 20(69%) in plasma transfusion group Vs. 09(31%) in conventional
therapy group (p=0.015). The hospital stay was comparable between two groups The relative risk ratio was 2.22 with 95%
CI (1.12-4.39).
Conclusions: There was no therapeutic benefit in Covid patients treated with convalescent plasma as compared to
conventional treatment.
References
National Health Commission of the People’s Republic of
China. Update on the novel coronavirus pneumonia outbreak
(Feb 16, 2020). https://www.nhc.gov.cn/ xcs/yqtb/202002/
da875d74445bb537ab014e7a1c6.shtml.
Report of the WHO-China Joint Mission on Coronavirus
Disease 2019 (COVID-19). 16–24 February 2020.
Chang JC. Sepsis and septic shock: endothelial molecular
pathogenesis associated with vascular microthrombotic disease.
Thromb J. 2019;17:10. doi: https://doi.org/10.1186/s12959-
-0198-4.
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A
novel treatment approach to the novel coronavirus: an argument
for the use of therapeutic plasma exchange for fulminant
COVID-19. Crit Care. 2020;24(1):128. Published 2020 Apr
doi: https://doi.org/10.1186/s13054-020-2836-4.
Joyner MJ, Bruno KA, Klassen SA, et al. Safety update:
COVID-19 convalescent plasma in 20,000 hospitalized
patients. Mayo Clin Proc 2020;95:1888-97. doi:
https://doi.org/10.1016/j.mayocp.2020.06.028.
Joyner MJ, Senefeld JW, Klassen SA, Mills JR, Johnson PW,
Theel ES, et al. Effect of Convalescent Plasma on Mortality
among Hospitalized Patients with COVID-19: Initial ThreeMonth Experience. medRxiv. 2020 Aug 12:2020.08.12.
doi: https://doi.org/10.1101/ 2020.08.12.20169359.
Simonovich VA, Burgos Pratx LD, Scibona P, Beruto MV,
Vallone MG, et al. A randomized trial of convalescent plasma
in Covid-19 severe pneumonia. N Engl J Med. 2021 Feb
;384(7):619-629. doi: https://doi.org/10.1056 /NEJMoa
Avendano-Sola C, Ramos-Martinez A, Munez-Rubio E, RuizAntoran B, de Molina RM, et al. Convalescent plasma for
COVID-19: a multicenter, randomized clinical trial. MedRxiv.
Jan 1. doi: https://doi.org/10.1101/2020.08.26.20182444.
National Institute of Health: COVID-19 . (2020). Accessed:
April 24, 2022: DOI: https://www.nih.org.pk/novelcoranavirus-
-ncov/
Medcalc—Relative Risk Calculator; 2017; Available online:
https://www.medcalc.org/calc/relative_risk.php (accessed on
th Sept 2021).
Sistrom CL, Garvan CW (January 2004). "Proportions, odds,
and risk". Radiology. 230 (1): 12–9. doi: https://doi.org/
1148/ radiol.2301031028.
Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai
N, et al. Estimates of the severity of coronavirus disease 2019:
a model-based analysis. The Lancet infectious diseases. 2020
Jun 1;20(6):669-77. doi: https://doi.org/10.1016/S1473-
(20)30243-7.
Recovery Collaborative Group. “Convalescent plasma in
patients admitted to hospital with COVID-19 (RECOVERY):
a randomised controlled, open-label, platform trial.” Lancet
(London, England) vol. 397,10289 (2021): 2049-2059.
https://doi.org/10.1016/S0140-6736(21)00897-7.
Carter C, Osborn M, Agagah G, Aedy H, Notter J. COVID-
disease: invasive ventilation. Clinics in Integrated Care.
;1:100004. doi: https://doi.org/10.1016/j.intcar.2020.
Madariaga ML, Guthmiller JJ, Schrantz S, Jansen MO,
Christensen C, Kumar M. Clinical predictors of donor antibody
titre and correlation with recipient antibody response in a
COVID-19 convalescent plasma clinical trial. Journal of
internal medicine. 2021;289(4):559-73. doi: https://doi.org/
1111/joim.13185.
Mahapatra S, Pati S. Constraints and challenges in convalescent
plasma collection amidst the Covid 19 pandemic- strategies
and recommendations to overcome these. Transfus Clin Biol.
;28(2):175-79. doi: https://doi.org/10.1016/ j.tracli.2021
.02.003.
Sheng, L., Wang, X., Tang, N. et al. Clinical characteristics
of moderate and severe cases with COVID-19 in Wuhan,
China: a retrospective study. Clin Exp Med 21, 35–39 (2021).
doi: https://doi.org/10.1007/s10238-020-00662-z.
Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E,
Berry S, et al. Risk factors and disease profile of postvaccination SARS-CoV-2 infection in UK users of the COVID
Symptom Study app: a prospective, community-based, nested,
case-control study. The Lancet Infectious Diseases. 2021 Sep
doi: https://doi.org/10.1016/S1473-3099(21)00460-6.
Ñamendys-Silva SA, Gutiérrez-Villaseñor A, RomeroGonzález JP. Hospital mortality in mechanically ventilated
COVID-19 patients in Mexico. Intensive Care Med. 2020.
doi: https://doi.org/10.1007/s00134-020-06256-3.
Mitra AR, Fergusson NA, Lloyd-Smith E, et al. Baseline
characteristics and outcomes of patients with COVID-19
admitted to intensive care units in Vancouver, Canada: a case
series. CMAJ. 2020;192: E694–701. doi: https://doi.org/
1503/ cmaj.200794.
Möhlenkamp, S., & Thiele, H. (2020). Ventilation of COVID-
patients in intensive care units. Beatmung von COVID-
-Patienten auf Intensivstationen. Herz, 45(4), 329–331. doi:
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Lubna Meraj , Muhammad Usman, Nadia Shams, Muhammad Umar, Sidra Tahir, Nasim Akhtar, Muhammad Khalid Mehmood Randhawa, Asif Majid, Ashar Alamgir
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of Bahria University Medical & Dental College is an open access journal and is licensed under CC BY-NC 4.0. which permits unrestricted non commercial use, distribution and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0 
